KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Assets Average: 2011-2025

Historic Assets Average for Nektar Therapeutics (NKTR) over the last 14 years, with Sep 2025 value amounting to $254.4 million.

  • Nektar Therapeutics' Assets Average fell 21.87% to $254.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $254.4 million, marking a year-over-year decrease of 21.87%. This contributed to the annual value of $350.9 million for FY2024, which is 36.69% down from last year.
  • Per Nektar Therapeutics' latest filing, its Assets Average stood at $254.4 million for Q3 2025, which was up 9.73% from $231.9 million recorded in Q2 2025.
  • Nektar Therapeutics' 5-year Assets Average high stood at $1.5 billion for Q1 2021, and its period low was $231.9 million during Q2 2025.
  • For the 3-year period, Nektar Therapeutics' Assets Average averaged around $383.4 million, with its median value being $369.7 million (2024).
  • Data for Nektar Therapeutics' Assets Average shows a maximum YoY crashed of 44.01% (in 2023) over the last 5 years.
  • Over the past 5 years, Nektar Therapeutics' Assets Average (Quarterly) stood at $1.2 billion in 2021, then crashed by 37.71% to $745.8 million in 2022, then slumped by 43.67% to $420.1 million in 2023, then declined by 27.19% to $305.9 million in 2024, then decreased by 21.87% to $254.4 million in 2025.
  • Its last three reported values are $254.4 million in Q3 2025, $231.9 million for Q2 2025, and $280.0 million during Q1 2025.